Need for Renal Replacement Therapy and Anti-infective Therapy Due to Severe Infection
Conditions
Brief summary
Approximately 300 patients have to be enrolled in the study. They are followed up until the end of ICU stay. Usually in clinical routine, patients suspected to have infection and simultaneously renal dysfunction making CVVHDF necessary. After enrolment blood and dialysate specimens are drawn and sent for analysis on specific time points. The analysis results are sent back to the study team at the Charité - Universitätsmedizin Berlin and enable them to optimize antiinfectiva treatment of the study patients. Data are used to test calculation tools and modify them if necessary.
Detailed description
Little data exist whether desired and necessary blood levels of antiinfective drugs are reached during renal replacement therapy. Drug producing companies are not able to come forward with appropriate dosing recommendation in patients needing renal replacement therapy. To achieve our study goal we plan: 1. To measure serum-concentrations of antiinfective drugs applied to the patients 2. To measure concentrations of antiinfective drugs in hemofiltration fluids. 3. To compare the actual measured concentrations with concentration predicted in known calculation tools. 4. To modify these calculation tools if necessary for better prediction.
Interventions
None listed
Sponsors
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients, age ≥ 18 years * Patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs
Exclusion criteria
* Pregnancy and lactation period. * Participation in a clinical intervention study * Lacking willingness to save and hand out data within the study * Accommodation in an institution due to an official or judicial order * The informed consent of the patient or the subject's legally acceptable representative can´t be obtained in time * Patient has a power of attorney or patient's provision, where he/she refuses participation in any clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibiotic clearance (l/h) | Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 5 days |
Secondary
| Measure | Time frame |
|---|---|
| 28-day mortality | The 28-days mortality will be assessed on the 28th study day |
Countries
Germany
Outcome results
None listed